INtRON Biotechnology (Korea) Performance
| 048530 Stock | KRW 5,690 190.00 3.45% |
The company retains a Market Volatility (i.e., Beta) of -0.55, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning INtRON Biotechnology are expected to decrease at a much lower rate. During the bear market, INtRON Biotechnology is likely to outperform the market. iNtRON Biotechnology right now retains a risk of 3.58%. Please check out INtRON Biotechnology total risk alpha, maximum drawdown, potential upside, as well as the relationship between the treynor ratio and value at risk , to decide if INtRON Biotechnology will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days iNtRON Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, INtRON Biotechnology is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Total Cashflows From Investing Activities | -41.3 B |
INtRON |
INtRON Biotechnology Relative Risk vs. Return Landscape
If you would invest 577,068 in iNtRON Biotechnology on November 3, 2024 and sell it today you would lose (8,068) from holding iNtRON Biotechnology or give up 1.4% of portfolio value over 90 days. iNtRON Biotechnology is generating 0.0404% of daily returns and assumes 3.5781% volatility on return distribution over the 90 days horizon. Simply put, 31% of stocks are less volatile than INtRON, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
INtRON Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for INtRON Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as iNtRON Biotechnology, and traders can use it to determine the average amount a INtRON Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0113
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 048530 |
Estimated Market Risk
| 3.58 actual daily | 31 69% of assets are more volatile |
Expected Return
| 0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average INtRON Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of INtRON Biotechnology by adding INtRON Biotechnology to a well-diversified portfolio.
INtRON Biotechnology Fundamentals Growth
INtRON Stock prices reflect investors' perceptions of the future prospects and financial health of INtRON Biotechnology, and INtRON Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on INtRON Stock performance.
| Return On Equity | 11.16 | |||
| Return On Asset | 0.0519 | |||
| Profit Margin | 0.34 % | |||
| Operating Margin | 0.31 % | |||
| Current Valuation | 734.71 B | |||
| Shares Outstanding | 29.88 M | |||
| Price To Earning | 313.17 X | |||
| Price To Sales | 9.32 X | |||
| Revenue | 29.31 B | |||
| EBITDA | 11.82 B | |||
| Cash And Equivalents | 75.17 B | |||
| Total Debt | 16.13 B | |||
| Debt To Equity | 10.90 % | |||
| Book Value Per Share | 2,284 X | |||
| Cash Flow From Operations | 16.47 B | |||
| Total Asset | 153.37 B | |||
| Retained Earnings | 2.09 B | |||
| Current Asset | 17.15 B | |||
| Current Liabilities | 2.86 B | |||
About INtRON Biotechnology Performance
By analyzing INtRON Biotechnology's fundamental ratios, stakeholders can gain valuable insights into INtRON Biotechnology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if INtRON Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if INtRON Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
iNtRON Biotechnology, Inc., a biotechnology company, develops bacterial bio-drugs for the treatment of infectious diseases. In addition, the company develops drugs targeting functional moieties, including axakacin, pterostilbene, methylated flavonoid, etc. for use in silver and brain industries. iNtRON Biotechnology, Inc. was founded in 1999 and is headquartered in Seongnam, South Korea. iNtRON Bio is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about iNtRON Biotechnology performance evaluation
Checking the ongoing alerts about INtRON Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for iNtRON Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| iNtRON Biotechnology had very high historical volatility over the last 90 days | |
| About 16.0% of the company shares are owned by insiders or employees |
- Analyzing INtRON Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether INtRON Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining INtRON Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating INtRON Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of INtRON Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of INtRON Biotechnology's stock. These opinions can provide insight into INtRON Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for INtRON Stock analysis
When running INtRON Biotechnology's price analysis, check to measure INtRON Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INtRON Biotechnology is operating at the current time. Most of INtRON Biotechnology's value examination focuses on studying past and present price action to predict the probability of INtRON Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INtRON Biotechnology's price. Additionally, you may evaluate how the addition of INtRON Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Stocks Directory Find actively traded stocks across global markets |